Published in EMBO Mol Med on April 22, 2013
Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer Cell (2014) 3.68
Genetic deletion of SEPT7 reveals a cell type-specific role of septins in microtubule destabilization for the completion of cytokinesis. PLoS Genet (2014) 0.97
The PAX2-null immunophenotype defines multiple lineages with common expression signatures in benign and neoplastic oviductal epithelium. J Pathol (2014) 0.86
The prognostic value and therapeutic target role of stathmin-1 in urinary bladder cancer. Br J Cancer (2014) 0.85
Epigenetic control of autophagy by microRNAs in ovarian cancer. Biomed Res Int (2014) 0.81
FUSE Binding Protein 1 Facilitates Persistent Hepatitis C Virus Replication in Hepatoma Cells by Regulating Tumor Suppressor p53. J Virol (2015) 0.80
Comparative Tissue Proteomics of Microdissected Specimens Reveals Novel Candidate Biomarkers of Bladder Cancer. Mol Cell Proteomics (2015) 0.79
Stathmin-dependent molecular targeting therapy for malignant tumor: the latest 5 years' discoveries and developments. J Transl Med (2016) 0.78
Common biological phenotypes characterize the acquisition of platinum-resistance in epithelial ovarian cancer cells. Sci Rep (2017) 0.76
Fluoro-edenite induces fibulin-3 overexpression in non-malignant human mesothelial cells. Oncol Lett (2016) 0.75
p27kip1 expression limits H-Ras-driven transformation and tumorigenesis by both canonical and non-canonical mechanisms. Oncotarget (2016) 0.75
Biomarker analysis of the MITO2 phase III trial of first-line treatment in ovarian cancer: predictive value of DNA-PK and phosphorylated ACC. Oncotarget (2016) 0.75
Effect of the p53-tristetraprolin-stathmin-1 pathway on trophoblasts at maternal-fetal interface. PLoS One (2017) 0.75
Stathmin is overexpressed and regulated by mutant p53 in oral squamous cell carcinoma. J Exp Clin Cancer Res (2017) 0.75
CDK6 protects epithelial ovarian cancer from platinum-induced death via FOXO3 regulation. EMBO Mol Med (2017) 0.75
Global cancer statistics. CA Cancer J Clin (2011) 185.92
Integrated genomic analyses of ovarian carcinoma. Nature (2011) 47.72
A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell (2006) 18.81
DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell (1997) 10.52
Modes of p53 regulation. Cell (2009) 9.31
Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. Cell (2012) 6.07
Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm. Hum Pathol (2011) 5.53
Human DNA-activated protein kinase phosphorylates serines 15 and 37 in the amino-terminal transactivation domain of human p53. Mol Cell Biol (1992) 3.68
Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol (2008) 3.68
Mutant p53 gain-of-function in cancer. Cold Spring Harb Perspect Biol (2010) 3.65
Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a. Genes Dev (1999) 3.41
Priming of centromere for CENP-A recruitment by human hMis18alpha, hMis18beta, and M18BP1. Dev Cell (2007) 3.25
Regulation of p53 in response to DNA damage. Oncogene (1999) 3.23
The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. Genes Dev (2008) 3.17
The oncoprotein 18/stathmin family of microtubule destabilizers. Curr Opin Cell Biol (2002) 3.11
Phosphorylation of p53 serine 15 increases interaction with CBP. J Biol Chem (1998) 2.97
p53: traffic cop at the crossroads of DNA repair and recombination. Nat Rev Mol Cell Biol (2005) 2.78
DNA damage-inducible phosphorylation of p53 at N-terminal sites including a novel site, Ser20, requires tetramerization. EMBO J (1999) 2.50
p53 and its mutants in tumor cell migration and invasion. J Cell Biol (2011) 2.49
The role of mutant p53 in human cancer. J Pathol (2010) 2.49
Mutant p53 oncogenic functions are sustained by Plk2 kinase through an autoregulatory feedback loop. Cell Cycle (2011) 2.46
Identification of a highly potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor (NU7441) by screening of chromenone libraries. Bioorg Med Chem Lett (2004) 2.35
The role of stathmin in the regulation of the cell cycle. J Cell Biochem (2004) 2.05
A Pin1/mutant p53 axis promotes aggressiveness in breast cancer. Cancer Cell (2011) 1.95
Stathmin 1, a marker of PI3K pathway activation and regulator of microtubule dynamics, is expressed in early pelvic serous carcinomas. Gynecol Oncol (2011) 1.87
A role of DNA-PK for the metabolic gene regulation in response to insulin. Cell (2009) 1.84
An oncogenic form of p53 confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint control. Proc Natl Acad Sci U S A (1998) 1.83
Centromeres: unique chromatin structures that drive chromosome segregation. Nat Rev Mol Cell Biol (2011) 1.80
Ovarian cancer pathogenesis: a model in evolution. J Oncol (2009) 1.77
Inhibition of hsp90 compromises the DNA damage response to radiation. Cancer Res (2006) 1.68
The rebel angel: mutant p53 as the driving oncogene in breast cancer. Carcinogenesis (2012) 1.67
Stathmin: a protein with many tasks. New biomarker and potential target in cancer. Expert Opin Ther Targets (2011) 1.66
Ovarian carcinoma pathology and genetics: recent advances. Hum Pathol (2009) 1.65
Reactivation of mutant p53: molecular mechanisms and therapeutic potential. Oncogene (2007) 1.62
Protumorigenic overexpression of stathmin/Op18 by gain-of-function mutation in p53 in human hepatocarcinogenesis. Hepatology (2007) 1.48
EPAC and PKA allow cAMP dual control over DNA-PK nuclear translocation. Proc Natl Acad Sci U S A (2008) 1.43
Bub1 and BubR1: at the interface between chromosome attachment and the spindle checkpoint. Mol Cell Biol (2011) 1.29
Activation of DNA-PK by ionizing radiation is mediated by protein phosphatase 6. PLoS One (2009) 1.23
DNA damage-induced apoptosis requires the DNA-dependent protein kinase, and is mediated by the latent population of p53. EMBO J (2002) 1.21
p27Kip1 expression inhibits glioblastoma growth, invasion, and tumor-induced neoangiogenesis. Mol Cancer Ther (2008) 1.16
p53 gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma. J Clin Oncol (2000) 1.14
Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumors. Mol Cancer Res (2008) 1.05
Cell cycle-dependent expression and nucleolar localization of hCAP-H. Mol Biol Cell (2001) 0.99
A role for loss of p53 function in sensitivity of ovarian carcinoma cells to taxanes. Int J Cancer (2001) 0.98
RCS1, a substrate of APC/C, controls the metaphase to anaphase transition. Proc Natl Acad Sci U S A (2008) 0.92
A genomic and transcriptomic approach for a differential diagnosis between primary and secondary ovarian carcinomas in patients with a previous history of breast cancer. BMC Cancer (2010) 0.89
Peptide aptamers targeting mutant p53 induce apoptosis in tumor cells. Cancer Res (2008) 0.88
Stathmin is dispensable for tumor onset in mice. PLoS One (2012) 0.84
E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer. Cancer Cell (2008) 7.56
Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta (2006) 7.33
A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res (2006) 7.09
MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response. Proc Natl Acad Sci U S A (2012) 5.07
Protein kinase C beta and prolyl isomerase 1 regulate mitochondrial effects of the life-span determinant p66Shc. Science (2007) 3.92
Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis. Nat Cell Biol (2002) 3.55
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget (2011) 3.43
Familial cancer associated with a polymorphism in ARLTS1. N Engl J Med (2005) 3.35
Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul (2006) 3.32
The prolyl isomerase Pin1 reveals a mechanism to control p53 functions after genotoxic insults. Nature (2002) 3.02
Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging (Albany NY) (2011) 2.72
p27(Kip1)-stathmin interaction influences sarcoma cell migration and invasion. Cancer Cell (2005) 2.65
[18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. Eur J Nucl Med Mol Imaging (2006) 2.63
Local excision after preoperative chemoradiotherapy for rectal cancer: results of a multicenter phase II clinical trial. Dis Colon Rectum (2013) 2.52
miRNA signatures associate with pathogenesis and progression of osteosarcoma. Cancer Res (2012) 2.52
EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. Nat Med (2011) 2.46
The transcriptional coactivator Yes-associated protein drives p73 gene-target specificity in response to DNA Damage. Mol Cell (2005) 2.45
Cell membrane reactivity of MIB-1 antibody to Ki67 in human tumors: fact or artifact? Appl Immunohistochem Mol Morphol (2007) 2.21
iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72-polymorphic p53. Nat Genet (2006) 2.20
Direct p53 transcriptional repression: in vivo analysis of CCAAT-containing G2/M promoters. Mol Cell Biol (2005) 2.13
The prolyl isomerase Pin1 orchestrates p53 acetylation and dissociation from the apoptosis inhibitor iASPP. Nat Struct Mol Biol (2007) 2.13
Alterations of choline phospholipid metabolism in ovarian tumor progression. Cancer Res (2005) 2.11
Human cutaneous melanomas lacking MITF and melanocyte differentiation antigens express a functional Axl receptor kinase. J Invest Dermatol (2011) 2.09
Modulation of mismatch repair and genomic stability by miR-155. Proc Natl Acad Sci U S A (2010) 2.05
MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2). Proc Natl Acad Sci U S A (2010) 1.99
Overexpression of the HMGA2 gene in transgenic mice leads to the onset of pituitary adenomas. Oncogene (2002) 1.99
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance. Oncotarget (2012) 1.96
A Pin1/mutant p53 axis promotes aggressiveness in breast cancer. Cancer Cell (2011) 1.95
Physical interaction with human tumor-derived p53 mutants inhibits p63 activities. J Biol Chem (2002) 1.91
Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response. Oncotarget (2012) 1.85
BRD7 is a candidate tumour suppressor gene required for p53 function. Nat Cell Biol (2010) 1.76
Prognosis of women with primary breast cancer diagnosed during pregnancy. J Clin Oncol (2013) 1.71
The rebel angel: mutant p53 as the driving oncogene in breast cancer. Carcinogenesis (2012) 1.67
Stathmin: a protein with many tasks. New biomarker and potential target in cancer. Expert Opin Ther Targets (2011) 1.66
Activation of phosphatidylcholine cycle enzymes in human epithelial ovarian cancer cells. Cancer Res (2010) 1.65
Stathmin activity influences sarcoma cell shape, motility, and metastatic potential. Mol Biol Cell (2008) 1.62
Clinical presentation and outcome of colorectal cancer in HIV-positive patients: a clinical case-control study. Onkologie (2009) 1.58
HCV-associated B cell clonalities in the liver do not carry the t(14;18) chromosomal translocation. Hepatology (2005) 1.57
GSK-3 as potential target for therapeutic intervention in cancer. Oncotarget (2014) 1.56
Pin1 links the activities of c-Abl and p300 in regulating p73 function. Mol Cell (2004) 1.55
PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches. Cell Cycle (2009) 1.54
Transgenic mice overexpressing the wild-type form of the HMGA1 gene develop mixed growth hormone/prolactin cell pituitary adenomas and natural killer cell lymphomas. Oncogene (2005) 1.53
Caspase-dependent regulation of histone deacetylase 4 nuclear-cytoplasmic shuttling promotes apoptosis. Mol Biol Cell (2004) 1.51
Impact of biospecimens handling on biomarker research in breast cancer. BMC Cancer (2009) 1.51
The use of a tropism-modified measles virus in folate receptor-targeted virotherapy of ovarian cancer. Clin Cancer Res (2006) 1.50
A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis. Proc Natl Acad Sci U S A (2013) 1.44
The prolyl-isomerase Pin1 is a Notch1 target that enhances Notch1 activation in cancer. Nat Cell Biol (2009) 1.44
The tumor suppressor functions of p27(kip1) include control of the mesenchymal/amoeboid transition. Mol Cell Biol (2009) 1.43
Integrated microRNA and mRNA signatures associated with survival in triple negative breast cancer. PLoS One (2013) 1.43
Role of microRNAs in ovarian cancer pathogenesis and potential clinical implications. Int J Biochem Cell Biol (2009) 1.43
Akt as a therapeutic target in cancer. Expert Opin Ther Targets (2008) 1.41
EMILIN-1 deficiency induces elastogenesis and vascular cell defects. Mol Cell Biol (2004) 1.41
Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways. J Cell Physiol (2011) 1.40
Feasibility and diagnostic agreement in teledermatopathology using a virtual slide system. Hum Pathol (2007) 1.39
The involvement of the transcription factor Yin Yang 1 in cancer development and progression. Cell Cycle (2009) 1.38
M-CAM expression as marker of poor prognosis in epithelial ovarian cancer. Int J Cancer (2006) 1.38
The tumor microenvironment in hepatocellular carcinoma (review). Int J Oncol (2012) 1.38
Targeted intraoperative radiotherapy impairs the stimulation of breast cancer cell proliferation and invasion caused by surgical wounding. Clin Cancer Res (2008) 1.34
Haploinsufficiency of the Hmga1 gene causes cardiac hypertrophy and myelo-lymphoproliferative disorders in mice. Cancer Res (2006) 1.34
Gene alterations in the PI3K/PTEN/AKT pathway as a mechanism of drug-resistance (review). Int J Oncol (2011) 1.34
MiR-506 inhibits multiple targets in the epithelial-to-mesenchymal transition network and is associated with good prognosis in epithelial ovarian cancer. J Pathol (2014) 1.33
The side population of ovarian cancer cells is a primary target of IFN-alpha antitumor effects. Cancer Res (2008) 1.33
Transcriptional activation of the cyclin A gene by the architectural transcription factor HMGA2. Mol Cell Biol (2003) 1.32
Melanoma: molecular pathogenesis and emerging target therapies (Review). Int J Oncol (2009) 1.31
HMGA1 promotes metastatic processes in basal-like breast cancer regulating EMT and stemness. Oncotarget (2013) 1.29
Extracellular matrix: a matter of life and death. Connect Tissue Res (2008) 1.28
microRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers. Oncotarget (2014) 1.28